5. 進行性核上性麻痺 Progressive supranuclear palsy Clinical trials / Disease details
臨床試験数 : 95 / 薬物数 : 119 - (DrugBank : 40) / 標的遺伝子数 : 65 - 標的パスウェイ数 : 108
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03446807 (ClinicalTrials.gov) | December 2021 | 20/2/2018 | Safety and Efficacy of Droxidopa for Fatigue in Patients With Parkinsonism | Safety and Efficacy of Droxidopa for Fatigue in Patients With Parkinsonism | Parkinson Disease;Multiple System Atrophy;Progressive Supranuclear Palsy | Drug: Droxidopa;Drug: Placebo Oral Tablet | Loma Linda University | H. Lundbeck A/S | Not yet recruiting | 50 Years | N/A | All | 32 | Phase 2 | United States |
| 2 | NCT04993768 (ClinicalTrials.gov) | October 15, 2021 | 19/7/2021 | A Phase 2a Study of TPN-101 in Patients With Progressive Supranuclear Palsy (PSP) | A Phase 2a Study of TPN-101 in Patients With Progressive Supranuclear Palsy (PSP) | Progressive Supranuclear Palsy | Drug: TPN-101, 100 mg/day;Drug: TPN-101, 200 mg/day;Drug: TPN-101, 400 mg/day;Drug: Placebo | Transposon Therapeutics, Inc. | NULL | Recruiting | 41 Years | 86 Years | All | 40 | Phase 2 | United States |
| 3 | NCT04937530 (ClinicalTrials.gov) | June 23, 2021 | 16/6/2021 | RT001 in Patients With Progressive Supranuclear Palsy (PSP) PROGRESSIVE SUPRANUCLEAR PALSY | A Randomized, Double-blind, Controlled, Phase 2 Study to Assess Efficacy, Long Term Safety and Tolerability of RT001 in Subjects With Progressive Supranuclear Palsy | Progressive Supranuclear Palsy | Drug: RT001;Drug: Placebo | Retrotope, Inc. | NULL | Recruiting | 40 Years | 80 Years | All | 40 | Phase 2 | Germany |
| 4 | NCT04539041 (ClinicalTrials.gov) | February 16, 2021 | 25/8/2020 | Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of NIO752 in Progressive Supranuclear Palsy | A Randomized, Participant, Investigator and Sponsor Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of Intrathecally Administered NIO752 in Participants With Progressive Supranuclear Palsy | Progressive Supranuclear Palsy (PSP) | Drug: antisense oligonucleotide;Drug: placebo | Novartis Pharmaceuticals | NULL | Recruiting | 40 Years | 75 Years | All | 66 | Phase 1 | United States;Canada;Germany;United Kingdom |
| 5 | NCT04253132 (ClinicalTrials.gov) | January 1, 2021 | 17/12/2019 | Evaluation of Tolfenamic Acid in Individuals With PSP at 12-Weeks | A Phase 2a Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Tolfenamic Acid for the Treatment of Progressive Supranuclear Palsy | Progressive Supranuclear Palsy | Drug: Tolfenamic Acid;Drug: Placebos | NeuroTau, Inc. | The Cleveland Clinic | Not yet recruiting | 40 Years | 85 Years | All | 24 | Phase 1/Phase 2 | United States |
| 6 | NCT04008355 (ClinicalTrials.gov) | June 22, 2020 | 18/6/2019 | A Study to Assess Tolerability, Safety, Pharmacokinetics and Effect of AZP2006 in Patients With PSP | A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess Tolerability, Safety, Pharmacokinetics and Effect of AZP2006 on Cerebrospinal Fluid Biomarkers in 36 Patients With Progressive Supranuclear Palsy | Progressive Supranuclear Palsy | Drug: AZP2006 oral solution;Drug: Placebo oral solution | AlzProtect SAS | NULL | Recruiting | 40 Years | 80 Years | All | 36 | Phase 2 | France |
| 7 | NCT04185415 (ClinicalTrials.gov) | December 3, 2019 | 2/12/2019 | A Participant-Blind, Investigator-Blind, Placebo-Controlled, Phase 1b Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of UCB0107 in Study Participants With Progressive Supranuclear Palsy (PSP) | A Participant-Blind, Investigator-Blind, Placebo-Controlled, Phase 1b Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of UCB0107 in Study Participants With Progressive Supranuclear Palsy (PSP) | Progressive Supranuclear Palsy | Drug: bepranemab;Drug: Placebo | UCB Biopharma SRL | NULL | Completed | 40 Years | N/A | All | 25 | Phase 1 | Belgium;Germany;Spain;United Kingdom |
| 8 | NCT03924414 (ClinicalTrials.gov) | November 15, 2019 | 2/4/2019 | Trial of Parkinson's And Zoledronic Acid | TOPAZ: Trial of Parkinson's And Zoledronic Acid A Randomized Placebo-controlled Trial of Zoledronic Acid for the Prevention of Fractures in Patients With Parkinson's Disease | Parkinson Disease;Osteoporosis;Parkinsonism;Parkinson's Disease and Parkinsonism;Atypical Parkinsonism;Progressive Supranuclear Palsy;Multiple System Atrophy;Vascular Parkinsonism;Dementia With Lewy Bodies | Drug: Zoledronic Acid 5Mg/Bag 100Ml Inj;Other: Placebo | California Pacific Medical Center Research Institute | National Institute on Aging (NIA);University of California, San Francisco;Duke University;University of Pittsburgh;Parkinson's Foundation | Recruiting | 60 Years | N/A | All | 3500 | Phase 4 | United States |
| 9 | NCT04184063 (ClinicalTrials.gov) | September 16, 2019 | 29/7/2019 | Study of NBMI Treatment in Patients With Atypical Parkinsons (PSP or MSA) | A Pilot Exploratory, Randomised, Placebo-controlled, Double Blinded, Cross-over , Phase 2a Study to Explore Efficacy and Safety of NBMI Treatment in Patients With Progressive Supranuclear Palsy (PSP) or Multiple System Atrophy (MSA) | Progressive Supranuclear Palsy;Multiple System Atrophy | Drug: NBMI;Other: Placebo | EmeraMed | NULL | Completed | 40 Years | 85 Years | All | 20 | Phase 2 | Slovenia |
| 10 | NCT04014387 (ClinicalTrials.gov) | June 2, 2019 | 11/4/2019 | Treatment of Disturbed Sleep in Progressive Supranuclear Palsy (PSP) | Treatment of Disturbed Sleep in Progressive Supranuclear Palsy (PSP) | Treatment | Drug: Suvorexant;Drug: Zolpidem;Drug: Placebo oral capsule | University of California, San Francisco | US Department of Veterans Affairs | Recruiting | 18 Years | N/A | All | 60 | Phase 4 | United States |
| 11 | EUCTR2018-000506-34-SI (EUCTR) | 04/02/2019 | 09/03/2018 | EMERA006- A pilot, exploratory, randomised, placebo-controlled, double blinded, cross-over, Phase 2a study to explore efficacy and safety of NBMI treatment in patients with Progressive Supranuclear Palsy (PSP) or Multiple System Atrophy (MSA). - EMERA006 | EMERA006- A pilot, exploratory, randomised, placebo-controlled, double blinded, cross-over, Phase 2a study to explore efficacy and safety of NBMI treatment in patients with Progressive Supranuclear Palsy (PSP) or Multiple System Atrophy (MSA). - EMERA006 | PSP or MSA;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: NBMI Product Code: NBMI INN or Proposed INN: emeramide Other descriptive name: N1,N3-BIS(2-MERCAPTOETHYL) ISOPHTHALAMIDE | NBMI Science Ltd. | NULL | Not Recruiting | Female: yes Male: yes | 20 | Phase 2 | Slovenia | ||
| 12 | EUCTR2016-001635-12-ES (EUCTR) | 04/07/2018 | 10/05/2018 | A Study to Evaluate the Efficacy, Safety , Tolerability and Pharmacokinetics of ABBV-8E12 in Subjects with Progressive Supranuclear Palsy. | A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Progressive Supranuclear Palsy | Progressive Supranuclear Palsy MedDRA version: 20.0;Level: PT;Classification code 10036813;Term: Progressive supranuclear palsy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Code: ABBV-8E12 INN or Proposed INN: ABBV-8E12 Other descriptive name: ABBV-8E12 Product Code: ABBV-8E12 INN or Proposed INN: ABBV-8E12 Other descriptive name: ABBV-8E12 | AbbVie Deutschland GmbH & Co. KG | NULL | Not Recruiting | Female: yes Male: yes | 330 | Phase 2 | United States;Canada;Spain;Australia;Germany;Italy | ||
| 13 | EUCTR2016-002554-21-GR (EUCTR) | 09/03/2018 | 02/01/2018 | Study of BIIB092 in Participants With Progressive Supranuclear Palsy | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BIIB092 in Participants with Progressive Supranuclear Palsy | Progressive supranuclear palsy MedDRA version: 20.0;Level: PT;Classification code 10036813;Term: Progressive supranuclear palsy;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Code: BIIB092 INN or Proposed INN: BIIB092 Other descriptive name: BIIB092 | Biogen Idec Research Limited | NULL | Not Recruiting | Female: yes Male: yes | 396 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no | United States;Greece;Spain;Austria;Russian Federation;United Kingdom;Italy;France;Canada;Australia;Germany;Japan;Korea, Republic of | ||
| 14 | EUCTR2016-002554-21-IT (EUCTR) | 24/01/2018 | 25/05/2021 | A study to test the effectiveness and safety of test product BIIB092 compared to placebo in participants with progressive supranuclear palsy, arare and progressive condition that can cause problems with balance, movement, vision, speech and swallowing | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BIIB092 in Participants with Progressive Supranuclear Palsy - A randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and s | Progressive supranuclear palsy MedDRA version: 21.1;Level: PT;Classification code 10036813;Term: Progressive supranuclear palsy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: BIIB092 Product Code: [BIIB092] INN or Proposed INN: BIIB092 | BIOGEN IDEC RESEARCH LIMITED | NULL | Not Recruiting | Female: yes Male: yes | 459 | Phase 2 | United States;Greece;Spain;Austria;Russian Federation;United Kingdom;Italy;France;Canada;Australia;Germany;Netherlands;Japan;Korea, Republic of | ||
| 15 | NCT03391765 (ClinicalTrials.gov) | January 24, 2018 | 2/1/2018 | An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP) | An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP) | Progressive Supranuclear Palsy (PSP) | Drug: ABBV-8E12;Drug: Placebo solution for IV infusion on Day 15 | AbbVie | NULL | Terminated | 40 Years | N/A | All | 142 | Phase 2 | United States;Australia;Canada;Italy;Japan;France |
| 16 | EUCTR2016-001635-12-DE (EUCTR) | 23/11/2017 | 20/02/2017 | A Study to Evaluate the Efficacy, Safety , Tolerability and Pharmacokinetics of ABBV-8E12 in Subjects with Progressive Supranuclear Palsy. | A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Progressive Supranuclear Palsy | Progressive Supranuclear Palsy MedDRA version: 20.0;Level: PT;Classification code 10036813;Term: Progressive supranuclear palsy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Code: ABBV-8E12 Product Code: ABBV-8E12 Other descriptive name: ABBV-8E12 | AbbVie Deutschland GmbH & Co. KG | NULL | Not Recruiting | Female: yes Male: yes | 330 | Phase 2 | United States;Canada;Spain;Australia;Germany;Italy | ||
| 17 | EUCTR2016-001635-12-FR (EUCTR) | 26/10/2017 | 17/07/2017 | A Study to Evaluate the Efficacy, Safety , Tolerability and Pharmacokinetics of ABBV-8E12 in Subjects with Progressive Supranuclear Palsy. | A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Progressive Supranuclear Palsy | Progressive Supranuclear Palsy MedDRA version: 20.0;Level: PT;Classification code 10036813;Term: Progressive supranuclear palsy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Code: ABBV-8E12 | AbbVie Deutschland GmbH & Co. KG | NULL | Not Recruiting | Female: yes Male: yes | 180 | Phase 2 | United States;France;Canada;Spain;Australia;Germany;Italy | ||
| 18 | EUCTR2016-002554-21-DE (EUCTR) | 18/08/2017 | 19/04/2017 | A study of BIIB092 in participants with Progressive Supranuclear Palsy | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BIIB0092 in Participants with Progressive Supranuclear Palsy | Progressive supranuclear palsy MedDRA version: 21.1;Level: PT;Classification code 10036813;Term: Progressive supranuclear palsy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Code: BIIB092 INN or Proposed INN: BIIB092 Other descriptive name: BIIB092 | Biogen Idec Research Limited | NULL | Not Recruiting | Female: yes Male: yes | 459 | Phase 2 | United States;Greece;Spain;Austria;Russian Federation;Italy;United Kingdom;France;Canada;Australia;Germany;Japan;Korea, Republic of | ||
| 19 | JPRN-JapicCTI-173627 | 01/8/2017 | 26/06/2017 | Study of BMS-986168 in Patients With Progressive Supranuclear Palsy (PASSPORT) | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BMS-986168 in Participants with Progressive Supranuclear Palsy | Progressive Supranuclear Palsy | Intervention name : BMS-986168 Dosage And administration of the intervention : BMS-986168 intravenous infusion on specified days Control intervention name : Placebo Dosage And administration of the control intervention : Placebo intravenous infusion on specified days | Bristol-Myers Squibb K.K. | NULL | 41 | 86 | BOTH | 396 | Phase 2 | NULL | |
| 20 | EUCTR2016-002554-21-GB (EUCTR) | 21/07/2017 | 10/04/2017 | Study of BIIB092 in Participants With Progressive Supranuclear Palsy | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BIIB092 in Participants with Progressive Supranuclear Palsy | Progressive supranuclear palsy MedDRA version: 21.1;Level: PT;Classification code 10036813;Term: Progressive supranuclear palsy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Code: BIIB092 INN or Proposed INN: BIIB092 Other descriptive name: BIIB092 | Biogen Idec Research Limited | NULL | Not Recruiting | Female: yes Male: yes | 459 | Phase 2 | Canada;Australia;Germany;Japan;Korea, Republic of;United States;Greece;Spain;Austria;Russian Federation;United Kingdom;Italy;France | ||
| 21 | EUCTR2016-002554-21-AT (EUCTR) | 30/06/2017 | 20/04/2017 | Study of BIIB092 in Participants With Progressive Supranuclear Palsy | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BIIB092 in Participants with Progressive Supranuclear Palsy | Progressive supranuclear palsy MedDRA version: 21.1;Level: PT;Classification code 10036813;Term: Progressive supranuclear palsy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Code: BIIB092 INN or Proposed INN: BIIB092 Other descriptive name: BIIB092 | Biogen Idec Research Limited | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 459 | Phase 2 | United States;Greece;Spain;Austria;Russian Federation;United Kingdom;Italy;France;Canada;Australia;Germany;Japan;Korea, Republic of | ||
| 22 | EUCTR2016-002554-21-ES (EUCTR) | 08/06/2017 | 24/04/2017 | A study to test the effectiveness and safety of test product BMS-986168 compared to placebo in participants with progressive supranuclear palsy, a rare and progressive condition that can cause problems with balance, movement, vision, speech and swallowing | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BMS-986168 in Participants with Progressive Supranuclear Palsy | Progressive supranuclear palsy MedDRA version: 19.1;Level: PT;Classification code 10036813;Term: Progressive supranuclear palsy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Code: BMS-986168 INN or Proposed INN: BMS986168 Other descriptive name: BMS986168 | Bristol-Myers Squibb International Corporation | NULL | Not Recruiting | Female: yes Male: yes | 396 | Phase 2 | United States;Greece;Spain;Austria;Russian Federation;Italy;United Kingdom;France;Canada;Australia;Germany;Netherlands;Japan;Korea, Republic of | ||
| 23 | NCT03068468 (ClinicalTrials.gov) | June 1, 2017 | 27/2/2017 | Study of BIIB092 in Participants With Progressive Supranuclear Palsy | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BIIB092 in Participants With Progressive Supranuclear Palsy | Supranuclear Palsy, Progressive | Drug: BIIB092;Drug: Placebo | Biogen | NULL | Terminated | 41 Years | 86 Years | All | 490 | Phase 2 | United States;Australia;Austria;Canada;France;Germany;Greece;Italy;Japan;Korea, Republic of;Russian Federation;Spain;United Kingdom |
| 24 | EUCTR2016-001635-12-IT (EUCTR) | 31/05/2017 | 05/02/2018 | A Study to Evaluate the Efficacy, Safety , Tolerability and Pharmacokinetics of ABBV-8E12 in Subjects with Progressive Supranuclear Palsy. | A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Progressive Supranuclear Palsy - NA | Progressive Supranuclear Palsy MedDRA version: 20.0;Level: PT;Classification code 10036813;Term: Progressive supranuclear palsy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: ABBV-8E12 Product Code: ABBV-8E12 INN or Proposed INN: ABBV-8E12 | ABBVIE DEUTSCHLAND GMBH & CO. KG | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 180 | Phase 2 | United States;Canada;Australia;Italy | ||
| 25 | NCT02985879 (ClinicalTrials.gov) | December 12, 2016 | 1/12/2016 | A Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Subjects With Progressive Supranuclear Palsy (PSP) | A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Progressive Supranuclear Palsy | Progressive Supranuclear Palsy | Drug: Placebo;Drug: ABBV-8E12 | AbbVie | NULL | Terminated | 40 Years | N/A | All | 378 | Phase 2 | United States;Australia;Canada;France;Germany;Italy;Japan;Spain |
| 26 | NCT02839642 (ClinicalTrials.gov) | July 26, 2016 | 30/6/2016 | Efficacy of RIVAstigmine on Motor, Cognitive and Behavioural Impairment in Progressive Supranuclear Palsy | RIVA-PSP: Efficacy of Rivastigmine on Motor, Cognitive and Behavioural Impairment in Progressive Supranuclear Palsy: A Randomised Double Blind Placebo-controlled Clinical Trial | Progressive Supranuclear Palsy (PSP) | Drug: Rivastigmine;Drug: Placebo | Assistance Publique Hopitaux De Marseille | NULL | Recruiting | 41 Years | 80 Years | All | 106 | Phase 3 | France |
| 27 | NCT02460094 (ClinicalTrials.gov) | October 2, 2015 | 20/5/2015 | Multiple Ascending Dose Study of Intravenously Administered BMS-986168 (BIIB092) in Patients With Progressive Supranuclear Palsy | A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of Intravenously Administered BMS-986168 in Patients With Progressive Supranuclear Palsy | Progressive Supranuclear Palsy | Drug: BIIB092;Drug: Placebo | Biogen | NULL | Completed | 41 Years | 86 Years | All | 48 | Phase 1 | United States |
| 28 | NCT02494024 (ClinicalTrials.gov) | July 2015 | 30/6/2015 | Safety, Tolerability, and Pharmacokinetics of C2N-8E12 in Subjects With Progressive Supranuclear Palsy | A Double-Blind, Placebo Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of C2N-8E12 in Subjects With Progressive Supranuclear Palsy | Progressive Supranuclear Palsy | Drug: Single dose C2N-8E12;Drug: Single dose placebo | C2N Diagnostics | NULL | Completed | 50 Years | 85 Years | All | 32 | Phase 1 | United States |
| 29 | EUCTR2013-003740-23-ES (EUCTR) | 04/02/2015 | 05/12/2013 | Evaluation of masitinib in the treatment of Progressive Supranuclear Palsy | A prospective, multicentre, randomised, double-blind, placebo-controlled, parallel groups, phase 2b/3 study to compare the efficacy and safety of masitinib versus placebo in the treatment of patients suffering from Progressive Supranuclear Palsy (PSP) | Progressive Supranuclear Palsy MedDRA version: 14.1;Level: PT;Classification code 10036813;Term: Progressive supranuclear palsy;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: masitinib 100mg Product Code: AB1010 INN or Proposed INN: Masitinib mesylate Other descriptive name: MASITINIB MESYLATE Product Name: masitinib 200mg Product Code: AB1010 INN or Proposed INN: Masitinib mesylate Other descriptive name: MASITINIB MESYLATE | AB Science | NULL | Not Recruiting | Female: yes Male: yes | 90 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no | Spain | ||
| 30 | NCT02133846 (ClinicalTrials.gov) | May 2014 | 6/5/2014 | Safety Study of TPI-287 to Treat CBS and PSP | A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Sequential Cohort, Dose-Ranging Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of TPI 287 in Patients With Primary Four Repeat Tauopathies: Corticobasal Syndrome or Progressive Supranuclear Palsy | Primary Four Repeat Tauopathies (4RT);Corticobasal Syndrome (CBS);Progressive Supranuclear Palsy (PSP);Corticobasal Degeneration (CBD) | Drug: TPI 287 2 mg/m2;Drug: TPI-287 20 mg/m2;Drug: Placebo;Drug: TPI-287 6.3 mg/m2 | University of California, San Francisco | CBD Solutions;Tau Consortium | Completed | 50 Years | 85 Years | All | 44 | Phase 1 | United States |
| 31 | EUCTR2012-005539-10-DE (EUCTR) | 29/04/2014 | 18/12/2013 | Clinical study to investigate the efficacy and safety of two dose levels of NT 201 versus placebo in treating chronic troublesome sialorrhea in various neurological conditions. | Prospective, randomized, double-blind, placebo-controlled, parallel-group multicenter study, with an extension period of dose-blinded active treatment, to investigate the efficacy and safety of two dose levels of NT 201 in treating chronic troublesome sialorrhea in various neurological conditions - SIAXI – Sialorrhea in Adults Xeomin Investigation | Chronic troublesome sialorrhea resulting from neurological conditions in adults with Parkinson's disease or atypical parkinsonism (multiple system atrophy, corticobasal degeneration or progressive supranuclear palsy), or after stroke or traumatic brain injury. MedDRA version: 18.1;Level: PT;Classification code 10039424;Term: Salivary hypersecretion;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Xeomin INN or Proposed INN: NT 101 Other descriptive name: BOTULINUM TOXIN TYPE A Trade Name: Xeomin INN or Proposed INN: NT 101 Other descriptive name: BOTULINUM TOXIN TYPE A | Merz Pharmaceuticals GmbH | NULL | Not Recruiting | Female: yes Male: yes | 180 | Phase 3 | United States;Poland;Germany | ||
| 32 | EUCTR2010-019159-23-GB (EUCTR) | 22/12/2010 | 08/10/2010 | A Phase 2/3, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy. | A Phase 2/3, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy. | Progressive Supranuclear Palsy MedDRA version: 14.0;Level: PT;Classification code 10036813;Term: Progressive supranuclear palsy;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Davunetide Product Code: AL-108 INN or Proposed INN: Davunetide | Allon Therapeutics Inc | NULL | Not Recruiting | Female: yes Male: yes | 300 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no | France;United States;Canada;Australia;Germany;United Kingdom | ||
| 33 | EUCTR2010-019159-23-DE (EUCTR) | 08/11/2010 | 27/08/2010 | A Phase 2/3, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy. | A Phase 2/3, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy. | Progressive Supranuclear Palsy MedDRA version: 14.1;Level: PT;Classification code 10036813;Term: Progressive supranuclear palsy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Davunetide Product Code: AL-108 INN or Proposed INN: Davunetide | Allon Therapeutics Inc | NULL | Not Recruiting | Female: yes Male: yes | 300 | Phase 2/3 | France;United States;Canada;Australia;Germany;United Kingdom | ||
| 34 | NCT01110720 (ClinicalTrials.gov) | October 2010 | 23/4/2010 | Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy | A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy | Progressive Supranuclear Palsy | Drug: Davunetide;Drug: Placebo | Allon Therapeutics | NULL | Completed | 41 Years | 85 Years | Both | 313 | Phase 2/Phase 3 | United States;Australia;Canada;France;Germany;United Kingdom |
| 35 | EUCTR2008-007520-26-DE (EUCTR) | 24/06/2010 | 13/11/2009 | A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to assess the Efficacy, Tolerability and Safety of Rasagiline in Subjects with Progressive Supranuclear Palsy (Phase III) | A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to assess the Efficacy, Tolerability and Safety of Rasagiline in Subjects with Progressive Supranuclear Palsy (Phase III) | Progressive Supranuclear Palsy MedDRA version: 12.0;Level: PT;Classification code 10036813;Term: Progressive supranuclear palsy | Trade Name: Azilect INN or Proposed INN: Rasagilin Other descriptive name: RASAGILINE MESILATE | Klinikum der Universität München | NULL | Not Recruiting | Female: yes Male: yes | Phase 3 | Germany | |||
| 36 | NCT01056965 (ClinicalTrials.gov) | January 2010 | 21/1/2010 | Davunetide (AL-108) in Predicted Tauopathies - Pilot Study | A 12 Week Randomized, Double Blind, Placebo-Controlled Pilot Study of Davunetide (NAP, AL-108) in Predicted Tauopathies | Predicted Tauopathies, Including;Progressive Supranuclear Palsy;Frontotemporal Dementia With Parkinsonism Linked to Chromosome 17;Corticobasal Degeneration Syndrome;Progressive Nonfluent Aphasia | Drug: davunetide (AL-108, NAP);Drug: Placebo nasal spray | University of California, San Francisco | NULL | Completed | 40 Years | 85 Years | All | 12 | Phase 1 | United States |
| 37 | NCT01187888 (ClinicalTrials.gov) | January 2010 | 20/8/2010 | Efficacy, Tolerability and Safety of Azilect in Subjects With Progressive Supranuclear Palsy | A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Rasagiline in Subjects With Progressive Supranuclear Palsy (Phase III) | Progressive Supranuclear Palsy | Drug: Rasagiline;Drug: Sugar pill | Prof. Dr. Stefan Lorenzl | Teva Pharmaceutical Industries;Ludwig-Maximilians - University of Munich | Terminated | 50 Years | 80 Years | Both | 44 | Phase 3 | Germany |
| 38 | NCT01049399 (ClinicalTrials.gov) | December 2009 | 13/1/2010 | Safety, Tolerability, and Efficacy of Two Different Oral Doses of NP031112 Versus Placebo in the Treatment of Patients With Mild-to-Moderate Progressive Supranuclear Palsy | A Double-Blind, Placebo-Controlled, Randomized, Parallel-Group Study Evaluating the Safety, Tolerability, and Efficacy of Two Different Oral Doses of NP031112, a GSK-3 Inhibitor, Versus Placebo in the Treatment of Patients With Mild-to-Moderate Progressive Supranuclear Palsy | Progressive Supranuclear Palsy | Drug: tideglusib;Drug: placebo | Noscira SA | i3 Research | Completed | 40 Years | 85 Years | Both | 146 | N/A | United States;Germany;Spain;United Kingdom |
| 39 | EUCTR2009-013097-40-ES (EUCTR) | 17/11/2009 | 29/07/2009 | Estudio doble-ciego, controlado con placebo, aleatorizado, de grupos paralelos, para evaluar la seguridad, tolerancia y eficacia de dos dosis orales diferentes de NP031112, un inhibidor de GSK3, versus placebo, como tratamiento de pacientes con Parálisis Supranuclear Progresiva leve o moderada | Estudio doble-ciego, controlado con placebo, aleatorizado, de grupos paralelos, para evaluar la seguridad, tolerancia y eficacia de dos dosis orales diferentes de NP031112, un inhibidor de GSK3, versus placebo, como tratamiento de pacientes con Parálisis Supranuclear Progresiva leve o moderada | Parálisis Supranuclear Progresiva leve o moderada MedDRA version: 9;Level: LLT;Classification code 10036813;Term: Progressive supranuclear palsy MedDRA version: 9;Level: PT;Term: Progressive supranuclear palsy | Product Name: NP031112 Product Code: NP031112 600mg Other descriptive name: 4-benzyl-2-naphtalen-1-yl-1,2,4-thiadiazolidine-3,5-dione Product Name: NP031112 Product Code: NP031112 800mg Other descriptive name: 4-benzyl-2-naphtalen-1-yl-1,2,4-thiadiazolidine-3,5-dione | Noscira S.A. | NULL | Not Recruiting | Female: yes Male: yes | 125 | Spain;Germany;United Kingdom | |||
| 40 | EUCTR2009-013097-40-DE (EUCTR) | 06/11/2009 | 30/07/2009 | A double-blind, placebo-controlled, randomized, parallel-group study evaluating thesafety, tolerability and efficacy of two different oral doses of NP031112, a GSK-3inhibitor, versus placebo in the treatment of patients with mild to moderateProgressive Supranuclear Palsy. - TAUROS | A double-blind, placebo-controlled, randomized, parallel-group study evaluating thesafety, tolerability and efficacy of two different oral doses of NP031112, a GSK-3inhibitor, versus placebo in the treatment of patients with mild to moderateProgressive Supranuclear Palsy. - TAUROS | Mild to Moderate Progressive Supranuclear Palsy MedDRA version: 12.0;Level: LLT;Classification code 10036813;Term: Progressive supranuclear palsy MedDRA version: 12.0;Level: PT;Term: Progressive supranuclear palsy | Product Name: NP031112 Product Code: NP031112 600mg Other descriptive name: 4-benzyl-2-naphtalen-1-yl-1,2,4-thiadiazolidine-3,5-dione Product Name: NP031112 Product Code: NP031112 800mg Other descriptive name: 4-benzyl-2-naphtalen-1-yl-1,2,4-thiadiazolidine-3,5-dione | Noscira S.A. | NULL | Not Recruiting | Female: yes Male: yes | 125 | United Kingdom;Spain;Germany | |||
| 41 | EUCTR2009-013097-40-GB (EUCTR) | 30/10/2009 | 23/07/2009 | A double-blind, placebo-controlled, randomized, parallel-group study evaluating the safety, tolerability and efficacy of two different oral doses of NP031112, a GSK-3 inhibitor, versus placebo in the treatment of patients with mild to moderate Progressive Supranuclear Palsy. - TAUROS | A double-blind, placebo-controlled, randomized, parallel-group study evaluating the safety, tolerability and efficacy of two different oral doses of NP031112, a GSK-3 inhibitor, versus placebo in the treatment of patients with mild to moderate Progressive Supranuclear Palsy. - TAUROS | Mild to Moderate Progressive Supranuclear Palsy MedDRA version: 12.0;Level: LLT;Classification code 10036813;Term: Progressive supranuclear palsy MedDRA version: 12.0;Level: PT;Term: Progressive supranuclear palsy | Product Name: NP031112 Product Code: NP031112 600mg Other descriptive name: 4-benzyl-2-naphtalen-1-yl-1,2,4-thiadiazolidine-3,5-dione Product Name: NP031112 Product Code: NP031112 800mg Other descriptive name: 4-benzyl-2-naphtalen-1-yl-1,2,4-thiadiazolidine-3,5-dione | Noscira S.A. | NULL | Not Recruiting | Female: yes Male: yes | 140 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no | Spain;Germany;United Kingdom | ||
| 42 | NCT00385710 (ClinicalTrials.gov) | November 2006 | 10/10/2006 | Trial of Valproic Acid in Patients With Progressive Supranuclear Palsy (Depakine) | Randomized Placebo-controlled Trial of Valproic Acid in Patients With Progressive Supranuclear Palsy | Progressive Supranuclear Palsy | Drug: valproic acid;Drug: Placebo | Nantes University Hospital | NULL | Completed | 45 Years | 75 Years | Both | 28 | Phase 2 | France |
| 43 | NCT00382824 (ClinicalTrials.gov) | September 2006 | 28/9/2006 | Effects of Coenzyme Q10 in Progressive Supranuclear Palsy (PSP) | Effects of Coenzyme Q10 in Progressive Supranuclear Palsy (PSP): A Multicenter, Randomized, Placebo-controlled, Double Blind Study | Progressive Supranuclear Palsy | Dietary Supplement: Coenzyme Q10;Other: Placebo | Lahey Clinic | NULL | Completed | 30 Years | N/A | All | 61 | N/A | United States |
| 44 | NCT00328874 (ClinicalTrials.gov) | May 2006 | 21/5/2006 | Study About Safety and Efficacy of Coenzyme Q10 in Progressive Supranuclear Palsy | Mono-center, Prospective, Double-blind, Placebo-controlled, Randomized Clinical Phase IIa Trial to Assess the Safety, Tolerability, and Immediate Biological Effects of Coenzyme Q10 - nanoQuinon® in Progressive Supranuclear Palsy | Progressive Supranuclear Palsy | Drug: Coenzyme Q10 | German Parkinson Study Group (GPS) | MSE Pharmazeutika GmbH, Louisenstr.114D-61348 Bad Homburg, Germany;Pitzer Stiftung;Philipps University Marburg Medical Center | Completed | 40 Years | 85 Years | All | 20 | Phase 2 | Germany |
| 45 | NCT00605930 (ClinicalTrials.gov) | April 2004 | 14/1/2008 | A Pilot Clinical Trial of Pyruvate, Creatine, and Niacinamide in Progressive Supranuclear Palsy. | Energy Metabolism in Neurodegenerative Diseases: A Randomized, Double Blind, Placebo-Controlled Clinical Pilot Trial of Pyruvate, Creatine, and Niacinamide in Progressive Supranuclear Palsy. | Progressive Supranuclear Palsy | Dietary Supplement: Pyruvate, creatine, niacinamide;Dietary Supplement: Placebo | University of Louisville | NULL | Completed | N/A | N/A | All | 20 | N/A | United States |
| 46 | NCT00532571 (ClinicalTrials.gov) | January 2004 | 18/9/2007 | Effects of Coenzyme Q10 in PSP and CBD | Effects of Coenzyme Q10 in PSP and CBD, A Randomized, Placebo-Controlled, Double Blind Cross Over Pilot Study | Progressive Supranuclear Palsy;Neurological Disorders | Drug: CoQ10 | Lahey Clinic | NULL | Completed | 40 Years | N/A | All | Phase 2/Phase 3 | United States | |
| 47 | EUCTR2016-002554-21-FR (EUCTR) | 15/06/2018 | A study to test the effectiveness and safety of test product BMS-986168 compared to placebo in participants with progressive supranuclear palsy, a rare and progressive condition that can cause problems with balance, movement, vision, speech and swallowing | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BMS-986168 in Participants with Progressive Supranuclear Palsy | Progressive supranuclear palsy MedDRA version: 20.0;Level: PT;Classification code 10036813;Term: Progressive supranuclear palsy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Code: BMS-986168 INN or Proposed INN: BMS986168 Other descriptive name: BMS986168 | Bristol-Myers Squibb International Corporation | NULL | NA | Female: yes Male: yes | 396 | Phase 2 | United States;Greece;Spain;Austria;Russian Federation;United Kingdom;Italy;France;Canada;Australia;Germany;Netherlands;Japan;Korea, Republic of |